Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24


51061 items
3:01 PM, Jun 19, 2018  |  BC Extra | Financial News

Decibel raises $55M in series C, names Scangos chairman

Decibel Therapeutics Inc. (Boston, Mass.) raised $55 million in a series C round from existing investors Third Rock Venture, GV, SR One and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and new investors Foresite Capital, Bessemer Venture Partners,...
2:23 PM, Jun 19, 2018  |  BC Extra | Company News

Foundation takeout boosts Roche's precision med capabilities

Roche (SIX:ROG; OTCQX:RHHBY) is acquiring the remaining shares of cancer diagnostics company Foundation Medicine Inc. (NASDAQ:FMI) that it does not already own for $137 per share in cash, or $2.4 billion. In 2015, Roche had acquired...
1:44 PM, Jun 19, 2018  |  BC Extra | Financial News

Syncona leads Freeline's £88M series B

Freeline Therapeutics Ltd. (London, U.K.) raised £88.4 million ($116.9 million) in a series B round which included £85 million from lead investor Syncona Ltd. (LSE:SYNC). Fellow founding investor UCL Technology Fund also participated, providing £3.4...
1:08 PM, Jun 19, 2018  |  BC Extra | Financial News

Qiming leads series A for Alpha Biopharma

Alpha Biopharma Inc. (Shanghai, China) raised $37 million in the first tranche of a planned $65 million series A round led by Qiming Venture Partners. The TF Fund and LYZZ Healthcare Venture Fund also participated. Alpha...
11:52 AM, Jun 19, 2018  |  BC Extra | Clinical News

Sarepta hits high on Phase I/IIa DMD readout

Sarepta Therapeutics Inc. (NASDAQ:SRPT) hit an all-time high Tuesday morning, adding $71.26 (68%) to $176.50 and pushing the company's market cap over $11 billion, after reporting preliminary data from a Phase I/IIa trial evaluating AAVrh74.MHCK7.micro-Dystrophin...
4:00 AM, Jun 19, 2018  |  BC Extra | Financial News

Emulate raises $36M series C to improve Organ-Chips offering

Emulate Inc. (Boston, Mass.) raised $36 million in a series C round led by Founders Fund. Fellow new investors ALS Investment Fund, SciFi VC and Glass Wall Syndicate also participated, as did undisclosed existing investors. Emulate...
4:56 PM, Jun 18, 2018  |  BC Extra | Company News

BridgeBio launches mitochondrial-focused subsidiary

BridgeBio Pharma LLC (Palo Alto, Calif.) launched Fortify Therapeutics Inc. on Monday with $20 million and an exclusive license to compounds from NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NEVPF) to treat Leber’s hereditary optic neuropathy. Fortify will...
4:50 PM, Jun 18, 2018  |  BC Extra | Clinical News

Hold for upcoming point-of-care CAR T trial sinks Ziopharm shares

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing....
4:31 PM, Jun 18, 2018  |  BC Extra | Politics & Policy

Payers, drugmakers face off over CAR T Medicare coverage

CMS is receiving contradictory recommendations in response to its request for comments about creating a national policy on Medicare payments for CAR T cancer therapies. Payers' and patient advocacy groups' comments urged CMS to institute...
4:13 PM, Jun 18, 2018  |  BC Extra | Preclinical News

Researchers identify new class of antimicrobials

Researchers from Technical University Berlin and the Deinobiotics subsidiary of Deinove S.A. (Euronext:ALDEI) identified a new class of antimicrobials, a group of ribosomally synthesized peptides called lipolanthines, in a paper published Monday in Nature Chemical...